Clinical Trial Update: A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix [Phase 2, Phase 3]

View source ↗

Summary

The study of amolimogene (ZYC101a) in patients with high-grade cervical intraepithelial lesions of the cervix has completed Phase 2 and Phase 3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Dysplasia

Drugs mentioned

• Amolimogene (ZYC101a) (amolimogene)

Snippet

Sponsor: Eisai Inc. | Conditions: Uterine Cervical Dysplasia | Phase 2, Phase 3 | Status: COMPLETED